New from Dunn Labortechnik: Antibodies and Antigens by Icon Medlab
Icon Medlab's diverse range of high-quality antibodies and antigens is now available from Dunn Labortechnik. Since 2010,…
Icon Medlab's diverse range of high-quality antibodies and antigens is now available from Dunn Labortechnik. Since 2010,…
The new cGMP filling line at Lonza’s Stein (CH) site will enable handling and filling of bioconjugates for commercia…
Klinische Studie mit HDP-101 in Europa und USA mit angepasstem Prüfplan und größerer Anzahl von europäischen Studienzent…
Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of…
In April 2021, the FDA approved the 100th monoclonal antibody as a therapeutic entity, a milestone that took 35 years to…
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinic Patient…
Times are changing and so are we – VelaLabs has grown up and is now moving into the next evolving step of the organizati…
In H1 2023, Lonza delivered CHF 3.1 billion sales and 5.6% CER1 sales growth, corresponding to around 10% CER underlying…
Preclinical data published in Frontiers in Immunology, a leading peer-reviewed journal Induction of pro-inflammatory…
Lonza to acquire Synaffix B.V., an innovative biotech company focused on antibody-drug conjugates (ADCs) Acquisition w…